Candel Therapeutics, Inc. (CADL) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-02

Key Insights

Nicoletta Loggia, a director of Candel Therapeutics, Inc. (CADL), acquired 779 stock options on March 31, 2026 with an exercise price of $4.9 per share. This indicates potential confidence in the company's future performance.
The stock options granted to Loggia are fully vested at the time of grant, suggesting the company may be compensating directors in equity to preserve cash.
The transaction represents a direct ownership stake for Loggia, which could align her interests with those of other shareholders.

Want the newest filings?

This analysis covers the filing from 2026-04-02. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-02

Insider Joseph C. Papa acquired 2,795 stock options of Candel Therapeutics, Inc. (CADL) on March 31, 2026, exercisable at $4.114 per share until March 31, 2036.
The stock option grant was made in lieu of normal quarterly cash payments, indicating the insider's confidence in the company's future prospects.
The substantial option grant and the fact that it was fully vested at the time of issuance suggest that the insider believes the stock is undervalued and expects it to appreciate significantly in the coming years.

Filed: 2026-04-02

The reporting person, Paul B. Manning, was granted a stock option to purchase 4,618 shares of the company's common stock at an exercise price of $4.114 per share.
The option was granted on 03/31/2026 and will expire on 03/31/2036, with the underlying shares fully vested at the time of grant.
This stock option grant appears to be in lieu of normal quarterly cash payments, indicating the company may be compensating directors through equity awards.

Filed: 2026-01-28

Francesca Barone, the Chief Scientific Officer of Candel Therapeutics, Inc., acquired 232,000 stock options with an exercise price of $6.01 and a 10-year vesting period.
The option grant suggests Barone's long-term commitment to the company and aligns her incentives with those of shareholders.
However, the large option grant may raise concerns about potential dilution for existing shareholders if exercised in the future.

Filed: 2026-01-28

The CEO, Paul Peter Tak, has been granted a stock option to acquire 629,000 shares of the company's common stock, which will vest over 4 years. This indicates the CEO's continued commitment to the company's long-term success.
The stock option grant is priced at $6.01 per share, which may suggest the company's stock price is expected to appreciate in the future.
The filing shows that the CEO is the only reporting person, indicating a highly concentrated ownership structure and the CEO's significant influence over the company's operations.

Filed: 2026-01-28

Charles Schoch, the Chief Financial Officer of Candel Therapeutics, Inc. (CADL), has been granted 232,000 stock options with a strike price of $6.01 and a 10-year expiration date. The options are subject to time-based vesting, with the shares underlying the options vesting in 48 equal monthly installments.
This transaction indicates that the company is incentivizing its CFO with long-term equity compensation, aligning his interests with those of the shareholders.
The significant number of options granted suggests that the company has confidence in the CFO's ability to drive the company's growth and performance over the next decade.

Filed: 2026-01-28

The Chief Medical Officer, William Garrett Nichols, was granted a stock option for 136,500 shares of Candel Therapeutics, Inc. (CADL) on January 26, 2026. This indicates the company's continued investment in the leadership team and aligns their interests with those of shareholders.
The stock option is subject to time-based vesting over a 4-year period, suggesting a long-term focus and commitment from the executive.
Insider transactions like this can provide insights into management's confidence in the company's future prospects and potential growth opportunities.

Filed: 2026-01-28

Seshu Tyagarajan, the Chief Technology Officer of Candel Therapeutics, Inc. (CADL), was granted a stock option to acquire 154,000 shares of the company's common stock, representing a sizable grant that could indicate confidence in the company's prospects.
The option has a 10-year term and vests over 4 years in equal monthly installments, aligning Tyagarajan's interests with those of long-term shareholders.
The transaction occurred on January 26, 2026, suggesting recent and active management participation in the company's equity.

Other reports for Candel Therapeutics, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.